Literature DB >> 20181885

Identification of new pathogenic players in lupus: autoantibody-secreting cells are present in nephritic kidneys of (NZBxNZW)F1 mice.

Stéphanie Lacotte1, Hélène Dumortier, Marion Décossas, Jean-Paul Briand, Sylviane Muller.   

Abstract

An important hallmark of systemic lupus erythematosus is the production of autoantibodies specific for nuclear Ags, among which nucleosomes and their constituents, DNA and histones. It is widely admitted that some of these autoantibodies contribute largely in lupus pathogenesis because of their nephritogenic potential. However, the underlying mechanisms are still debated. In this study, we analyzed the autoimmune response against histone H2B during the course of the disease in lupus-prone (NZBxNZW)F1 mice, both in lymphoid organs and kidneys, and we assessed its potential involvement in lupus pathogenicity. We found that the N-terminal region of histone H2B represents a preferential target for circulating autoantibodies, which kinetics of appearance positively correlates with disease development. Furthermore, immunization of preautoimmune (NZBxNZW)F1 mice with H2B peptide 1-25 accelerates the disease. Kidney eluates from diseased (NZBxNZW)F1 mice do contain IgG Abs reacting with this peptide, and this H2B sequence was found to be accessible to specific Ab probes in Ag-containing deposits detected in nephritic kidneys. Finally, compared with control normal mice and to young preautoimmune (NZBxNZW)F1 animals, the frequency of cells secreting autoantibodies reacting with peptide 1-25 was significantly raised in the spleen and bone marrow and most importantly on a pathophysiological point of view, locally, in nephritic kidneys of diseased (NZBxNZW)F1 mice. Altogether our results demonstrate the existence in (NZBxNZW)F1 mice of both a systemic and local B cell response targeting the N-terminal region of histone H2B, and highlight the potential implication of this nuclear domain in lupus pathology.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181885     DOI: 10.4049/jimmunol.0902595

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Plasma cells as an innovative target in autoimmune disease with renal manifestations.

Authors:  Falk Hiepe; Andreas Radbruch
Journal:  Nat Rev Nephrol       Date:  2016-02-29       Impact factor: 28.314

2.  Metformin Suppresses Systemic Autoimmunity in Roquinsan/san Mice through Inhibiting B Cell Differentiation into Plasma Cells via Regulation of AMPK/mTOR/STAT3.

Authors:  Seon-Yeong Lee; Su-Jin Moon; Eun-Kyung Kim; Hyeon-Beom Seo; Eun-Ji Yang; Hye-Jin Son; Jae-Kyung Kim; Jun-Ki Min; Sung-Hwan Park; Mi-La Cho
Journal:  J Immunol       Date:  2017-02-27       Impact factor: 5.422

3.  Long-term B cell depletion in murine lupus eliminates autoantibody-secreting cells and is associated with alterations in the kidney plasma cell niche.

Authors:  Wensheng Wang; Javier Rangel-Moreno; Teresa Owen; Jennifer Barnard; Sarah Nevarez; H Travis Ichikawa; Jennifer H Anolik
Journal:  J Immunol       Date:  2014-02-26       Impact factor: 5.422

4.  Ikaros Is a Negative Regulator of B1 Cell Development and Function.

Authors:  Alejandra Macias-Garcia; Beate Heizmann; MacLean Sellars; Patricia Marchal; Hayet Dali; Jean-Louis Pasquali; Sylviane Muller; Philippe Kastner; Susan Chan
Journal:  J Biol Chem       Date:  2016-02-03       Impact factor: 5.157

5.  Defective BTLA functionality is rescued by restoring lipid metabolism in lupus CD4+ T cells.

Authors:  Matthieu Sawaf; Jean-Daniel Fauny; Renaud Felten; Flora Sagez; Jacques-Eric Gottenberg; Hélène Dumortier; Fanny Monneaux
Journal:  JCI Insight       Date:  2018-07-12

6.  The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus.

Authors:  Yuan Liu; Josephine Ye; Luisa Shin Ogawa; Takayo Inoue; Qin Huang; John Chu; Richard C Bates; Weiwen Ying; Andrew J Sonderfan; Patricia E Rao; Dan Zhou
Journal:  PLoS One       Date:  2015-05-14       Impact factor: 3.240

7.  Autoantibodies against Modified Histone Peptides in SLE Patients Are Associated with Disease Activity and Lupus Nephritis.

Authors:  Jürgen Dieker; Jo H Berden; Marinka Bakker; Jean-Paul Briand; Sylviane Muller; Reinhard Voll; Christopher Sjöwall; Martin Herrmann; Luuk B Hilbrands; Johan van der Vlag
Journal:  PLoS One       Date:  2016-10-25       Impact factor: 3.240

8.  MicroRNAs in Acute Myeloid Leukemia and Other Blood Disorders.

Authors:  Yao Yuan; Siddha Kasar; Chingiz Underbayev; Sindhuri Prakash; Elizabeth Raveche
Journal:  Leuk Res Treatment       Date:  2012-06-17

9.  Early differentiated CD138(high) MHCII+ IgG+ plasma cells express CXCR3 and localize into inflamed kidneys of lupus mice.

Authors:  Stéphanie Lacotte; Marion Decossas; Carole Le Coz; Susana Brun; Sylviane Muller; Hélène Dumortier
Journal:  PLoS One       Date:  2013-03-08       Impact factor: 3.240

10.  Circulating TFH subset distribution is strongly affected in lupus patients with an active disease.

Authors:  Carole Le Coz; Aurélie Joublin; Jean-Louis Pasquali; Anne-Sophie Korganow; Hélène Dumortier; Fanny Monneaux
Journal:  PLoS One       Date:  2013-09-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.